{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Neoadjuvant Targeted Therapy in EGFR-Mutant Resectable Lung Adenocarcinoma"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "24 patients with stage IIA-IIIB EGFR-mutant lung adenocarcinoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "treated with neoadjuvant targeted therapy followed by surgery"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the objective response rate (ORR) post-treatment."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "24 patients with stage IIA-IIIB EGFR-mutant lung adenocarcinoma treated with neoadjuvant targeted therapy followed by surgery from July 2019 to October 2024."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All 24 patients achieved successful R0 resection."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The ORR was 83.3% (20/24), and the MPR was 37.5% (9/24), with 2 patients achieving pathological complete response (pCR)."
      },
      "Harms": {
        "score": 1,
        "evidence": "54.2% (13/24) experienced grade 1-2 adverse events, with no grade 3 or higher events reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}